https://doi.org/10.1016/j.vaccine.2019.09.099
Our analysis included 14 Asian countries that were estimated to have a total of 850,000 choleracases and 25,500 deaths in 2015 While, the WHO cholera report documented around 60,000 cholera casesand 28 deaths. We estimated around $20.2 million (I$74.4 m...illion) in out-of-pocket expenditures, $8.5million (I$30.1 million) in public sector costs, and $12.1 million (I$43.7 million) in lost productivity in2015. Lost productivity due to premature deaths was estimated to be $985.7 million (I$3,638.6 million).Our scenario analyses excluding mortality costs showed that the economic burden ranged from 20.3%($8.3 million) to 139.3% ($57.1 million) in high and low scenarios when compared to the base case sce-nario ($41 million) and was least at 10.1% ($4.1 million) when estimated based on cholera cases reportedto WHO
more
Morbidity and Mortality Weekly Report (MMWR) October 4, 2019 / 68(39);851–854
Sci Rep. 2016; 6: 25920. Published online 2016 May 16. doi: 10.1038/srep25920
Front. Psychiatry, 29 November 2018 | https://doi.org/10.3389/fpsyt.2018.00635
Int J Crit Illn Inj Sci. 2012 May-Aug; 2(2): 82–97.
doi: 10.4103/2229-5151.97273
PMCID: PMC3401822
PMID: 22837896
Open AccessPublished:March 28, 2019DOI:https://doi.org/10.1016/S1473-3099(18)30730-8
The Lancet Infectious Diseases
Afr J Psychiatry 2011;14:200-207
Indian J Psychiatry. 2017 Jan; 59(Suppl 1): S67–S73.
doi: 10.4103/0019-5545.196975: 10.4103/0019-5545.196975
Dialogues Clin Neurosci. 2017 Jun; 19(2): 93–107.
https://www.researchgate.net/publication/47460246_Mental_illness-stigma_and_discrimination_in_Zambia
In: Mental health nursing: dimensions of praxis. Oxford University Press, Melbourne, Australia, pp. 427-442. ISBN 9780195566963
This chapter introduces you to the importance of culturally based health and well-being and to health care delivered by mental health nurses. There is a need for mental h...ealth professionals to incorporate knowledge about these beliefs and to develop the skills to work with clients from cultures other than their own if they are to care for them effectivel
more
Cerebrum. 2016 Jul-Aug; 2016: cer-10-16.
Published online 2016 Jul 1.
BJPSYCH INTERNATIONALVOLUME 12NUMBER 4NOVEMBER 2015
The design of anaesthesia equipment for use in hospitals in the developing world must take intoaccount the local conditions, particularly whether reliable supplies of compressed oxygen andelectricity are available. Designs should ensure that maintenance is feasible locally. Internationalstandards sh...ould encourage the design of suitable equipment to ensure safe anaesthesia for patientsworldwide
Anaesthesia, 2007,62(Suppl. 1), pages 54–60
more
Desta et al. Int J Ment Health Syst (2018) 12:38 https://doi.org/10.1186/s13033-018-0217-z
BMC Public Health (2016) 16:766
DOI 10.1186/s12889-016-3455-5
Gurejeet al. BMC Health Services Research (2015) 15:242
DOI 10.1186/s12913-015-0911-3
After 100 years of chemotherapy with impractical and toxic drugs, an oral cure for human African trypanosomiasis (HAT) is available: Fexinidazole. In this case, we review the history of drug discovery for HAT with special emphasis on the discovery, pre-clinical development, and operational challenge...s of the clinical trials of fexinidazole. The screening of the Drugs for Neglected Diseases initiative (DNDi) HAT-library by the Swiss TPH had singled out fexinidazole, originally developed by Hoechst (now Sanofi), as the most promising of a series of over 800 nitroimidazoles and related molecules. In cell culture, fexinidazole has an IC50 of around 1 µM against Trypanosoma brucei and is more than 100-fold less toxic to mammalian cells. In the mouse model, fexinidazole cures both the first, haemolymphatic, and the second, meningoencephalitic stage of the infection, the latter at 100 mg/kg twice daily for 5 days. In patients, the clinical trials managed by DNDi and supported by Swiss TPH mainly conducted in the Democratic Republic of the Congo demonstrated that oral fexinidazole is safe and effective for use against first- and early second-stage sleeping sickness. Based on the positive opinion issued by the European Medicines Agency in 2018, the WHO has released new interim guidelines for the treatment of HAT including fexinidazole as the new therapy for first-stage and non-severe second-stage sleeping sickness caused by Trypanosoma brucei gambiense (gHAT). This greatly facilitates the diagnosis and treatment algorithm for gHAT, increasing the attainable coverage and paving the way towards the envisaged goal of zero transmission by 2030.
more